陈亚东，教授，博士生导师。江苏省“青蓝工程”优秀青年骨干教师，江苏省 “青蓝工程”中青年学术带头人，美国密歇根大学医学院综合癌症中心访问学者。主持和参与了多项国家自然科学基金、国家重大科技专项“重大新药创制”等科研项目；课题组与国内多个药企合作进行新药研发。申请国内专利14项，PCT专利3项；发表SCI论文100多篇。2015年研究团队发现的1.1类抗肿瘤新药以1.5亿元人民币里程金转让给上海复星医药，目前在美国、澳大利亚和中国大陆地区进行I期临床试验，2019年底获美国FDA授予孤儿药资格认定。
主要研究方向：
1）基于重大疾病的原创小分子药物发现；
2）基于人工智能的药物分子设计及其应用研究。
研究生招生专业：
100701药物化学（博士、学硕）；1007Z7医药大数据与人工智能（博士、学硕）；
105500药学-制药化学（专硕）；086000生物与医药-医药大数据与人工智能（专硕）。
联系方式：ydchen@cpu.edu.cn 办公室：江宁校区实验楼A203
近年代表性论文:
1. Zhijie, W.; Jiongheng, C.; Jiwei, R.; Yun, C.; Yingli, W.; Jie, C.; Kun, J.; Fei, H.; Zitian, C.; Tiancheng, S.; Shiyu, S.; Hao, H.; Yifan, Z.; Weifang, T.; Hongmei, L.*; Tao, L.*; Yadong, Chen.* and Shuai, L.* Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations. J. Med. Chem. 2021, 64, 19, 14664–14701.
2. Fei, J.; Qinghua, H.; Zhimin, Z.; Hongmei, L.; Huili, L.; Dewei, Z.; Hanwen, L.; Yu, M.; Jingjing, X.; Haifang, C.; Yong, C.; Yanle, Z.; Yanmin, Z.; Junyu, X.; Jiapeng, Z.*; Tao, L.* and Yadong, Chen.* Discovery of Benzo[cd]indol-2(1H)-ones and Pyrrolo[4,3,2-de]quinolin-2(1H)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis. J. Med. Chem. 2019, 62, 24, 11080–11107.
3. Jianhang, H.; Xinren, W.; Ruinan, D.; Xiaoyue, L.; Hongmei, L.; Tianyi, Z.; Junyu, X.; Chenhe, L.; Yanmin, Z.; Shaohua, H.; Weifang, T.*; Tao, L.* and Yadong, Chen.* Discovery of N-(4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-yl)-4-(4-methylpiperazin-1-yl)quinazolin-7-amine as a Novel, Potent, and Oral Cyclin-Dependent Kinase Inhibitor against Haematological Malignancies. J. Med. Chem. 2021, 64, 17, 12548–12571.
4. Yuqin, Z.; Yuxiang, M.; Weidong, Z.; Jianing, S.; Hua, W.; You, Z.; Hongmei, L.; Yanmin, Z.; Qianqian, G.; Bo, K.; Junyu, X.; Fei, J.; Xinren, W.; Shuwen, L.; Chenhe, L.; Haichun, L.; Tao, L.* and Yadong, Chen.* Identification of N-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis. J. Med. Chem. 2020, 63, 13, 6748–6773.
5. Zhijie, W.; Jiongheng, C.; Jie, C.; Wenqianzi, Y.; Yifan, Z.; Hongmei, L.; Tao, L.*; Yadong, Chen.* and Shuai, L.* FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance. J. Med. Chem. 2021, 64, 6, 2878–2900.
6. Yi Hua, Xiaobao Fang, Guomeng Xing, Yuan Xu, Li Liang, Chenglong Deng, Xiaowen Dai, Haichun Liu, Tao Lu*, Yanmin Zhang*, and Yadong Chen*. Effective Reaction-Based De Novo Strategy for Kinase Targets: A Case Study on MERTK Inhibitors. J. Chem. Inf. Model. 2022, https://doi.org/10.1021/acs.jcim.2c00068